Cannabinoid hyperemesis syndrome.

Authors: Jonathan A. Galli, Ronald Andari Sawaya, Frank K. Friedenberg
Current Drug Abuse Reviews, December 2011

Coinciding with the increasing rates of cannabis abuse has been the recognition of a new clinical condition known as Cannabinoid Hyperemesis Syndrome. Cannabinoid Hyperemesis Syndrome is characterized by chronic cannabis use, cyclic episodes of nausea and vomiting, and frequen…

Cannabinoid-opioid interaction in chronic pain.

Authors: D. I. Abrams, P. Couey, S. B. Shade, M. E. Kelly, N. L. Benowitz
Clinical Pharmacology & Therapeutics, December 2011

Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty-one individuals with chronic pa…

Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice.

Authors: Sara Ward, Michael Ramirez, Harshini Neelakantan, Ellen Walker
Anesthesia and Analgesia, October 2011

The taxane chemotherapeutic paclitaxel frequently produces peripheral neuropathy in humans. Rodent models to investigate mechanisms and treatments are largely restricted to male rats, whereas female mouse studies are lacking. We characterized a range of paclitaxel doses on col…

Cannabis use amongst patients with inflammatory bowel disease.

Authors: Simon Lal, Neeraj Prasad, Manijeh Ryan, Sabrena Tangri, Mark Silverberg, et al
European Journal of Gastroenterology & Hepatology, October 2011

BACKGROUND: Experimental evidence suggests the endogenous cannabinoid system may protect against colonic inflammation, leading to the possibility that activation of this system may have a therapeutic role in inflammatory bowel disease (IBD). Medicinal use of cannabis for chron…

Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress.

Authors: Érica M.Granjeiro, Felipe V.Gomes, Francisco S.Guimarães, Fernando M.A.Corrêa, Leonardo B.M. Resstel
Pharmacology Biochemistry and Behavior, October 2011

Systemic administration of cannabidiol (CBD), a non-psychotomimetic compound from Cannabis sativa, attenuates the cardiovascular and behavioral responses to restraint stress. Although the brain structures related to CBD effects are not entirely known, they could involve brains…

Review on clinical studies with cannabis and cannabinoids 2005-2009.

Based on the clinical results, cannabinoids present an interesting therapeutic potential mainly as analgesics in chronic neuropathic pain, appetite stimulants in debilitating diseases (cancer and AIDS), as well as in the treatment of multiple sclerosis.

Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model.

Authors: Rupal Pandey, Venkatesh L. Hegde, Mitzi Nagarkatti, Prakash S. Nagarkatti
Journal of Pharmacology and Experimental Therapeutics, September 2011

Allogeneic hematopoietic cell transplantation (HCT) is widely used to treat patients with life-threatening malignant and nonmalignant hematological diseases. However, allogeneic HCT often is accompanied by severe and lethal complications from graft-versus-host disease (GVHD)…

Beyond-THC Chemovar Evaluation Survey

The Society of Cannabis Clinicians developed a survey in 2011 that asked about patients’ responses to CBD-rich cannabis.

The dual neuroprotective-neurotoxic profile of cannabinoid drugs.

Authors: Yosef Sarne, Fadi Asaf, Miriam Fishbein, Mikhal Gafni, Ora Keren
British Journal of Pharmacology, August 2011

Extensive in vitro and in vivo studies have shown that cannabinoid drugs have neuroprotective properties and suggested that the endocannabinoid system may be involved in endogenous neuroprotective mechanisms. On the other hand, neurotoxic effects of cannabinoids in vitro and i…

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Authors: Ethan B. Russo
British Journal of Pharmacology, August 2011

Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated…

Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.

Authors: Gregory T. Carter, Aaron M. Flanagan, Mitchell Earleywine, Donald I. Abrams, et al
American Journal of Hospice and Palliative Medicine, August 2011

Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I…

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.

Authors: Sean D. McAllister, Ryuichi Murase, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, et al
Breast Cancer Research and Treatment, August 2011

Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Therefore, effective, targeted, and non-toxi…